Ongoing important trials
FIGHT-302 — pemigatinib vs gem/cis in FGFR2-rearranged CCA (terminated)
A Phase 3 Study to Evaluate Pemigatinib Versus Gemcitabine Plus Cisplatin in First-Line Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
- Phase
- Phase III
- Recruitment
- Terminated
- Results maturity
- Interim analysis
- Publication
- Congress only
- Regulatory approval
- No regulatory approval
- NCT
- NCT03656536
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? This trial closed early. Negative or incomplete results still advance science and are not deleted as ‘failures’.
What did it show? Attempted first-line confirmation of FGFR2-targeted strategy — early stop is itself a scientific lesson.
What is not proven? First-line superiority (underpowered / stopped after SoC change).
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Terminated for enrollment/SoC change; not for safety (registry). Do not confuse with FIGHT-202 (2L+).
Cancer / population: Biliary tract — Birinci basamak FGFR2-rearranged ileri CCA
Intervention: Pemigatinib
Primary endpoint: PFS
Limitations: Erken sonlanma — karşılaştırmalı çıkarım zayıf.